Sign inJoin waitlistJoin the waitlist

Mary-Elizabeth Percival

Associate Professor, Clinical Research Division, Fred Hutch · University of Washington School of Medicine

Credentials: · · · · ·

History

University of Washington School of Medicine
Present
University of Washington School of Medicine
Present

Hematology and Medical Oncology
Stanford University School of Medicine
2010–2013
Internal Medicine
University of California-San Francisco
2007–2010
Stanford University School of Medicine
Stanford University School of Medicine
2003–2007

Research

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Clinical Cancer Research · 2021 · 181 citations
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm
Journal of Clinical Oncology · 2020 · 53 citations
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms
Leukemia · 2018 · 44 citations

Roland Walter
34 papers
Anna Halpern
31 papers
EE
Elihu Estey
31 papers
PH
Paul Hendrie
25 papers
Pamela Becker
17 papers
Ryan Cassaday
17 papers
Bart Scott
13 papers
JA
Jacob Appelbaum
12 papers
Vivian Oehler
11 papers
Cristina Ghiuzeli
7 papers
Johnnie Orozco
6 papers
Sioban Keel
6 papers

Clinical trials

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Principal investigator · Recruiting · Phase 2
University of Washington
2018–2026
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
Principal investigator · Completed · Phase 2
University of Washington
2016–2020
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
Principal investigator · Completed
University of Washington
2015–2021
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Site PI · Unknown · Phase 1, Phase 2
Ascentage Pharma Group Inc.
2020–2025